Biologic Therapeutics Drugs Market by Product (Vaccines, Blood and Blood Products, Allergenic Extracts, Human Cells and Tissues, Gene Therapies, Protein, Cellular Therapies and Xenotransplantation Products), by Application (Rheumatoid Arthritis, Anemia, Cancer, Diabetes and Others), and By Source (Humans, Avian Cell Culture, Yeast, Bacteria, Insect Cell Culture and Xenotransplantation Products) - Global Opportunities and Industry Forecasts, 2018-2025

Get 20% Free Customization In This Report

Pharmaceuticals	LI_183928	Pages: NA	Mar 2019 \| 962 Views
Author(s) : NA	Tables: NA	Charts: NA	Formats*:

Biologic therapeutics drugs are genetically engineered proteins derived from human genetic material. They contain sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living entities such as cells and tissues. In addition, biologics drugs are derived from natural sources such as animals, humans, and microorganisms that are further utilized to make therapeutic products such as vaccines, blood components, and recombinant therapeutic proteins.

The major factors that contribute to the growth of the biologic therapeutic drugs market include increase in the prevalence of chronic diseases such as cancer, diabetes, & coronary artery diseases and a rise in geriatric population. Moreover, a large number of clinical trials and innovative R&D approaches to develop advanced drugs drive the market growth.

However, manufacturing difficulties due to the complexity of drug molecules hinder the market growth. Increase in R&D activities in the field of pharmaceutical industries and rise in therapeutical applications are anticipated to provide new opportunities for the market.

The biologic therapeutics drugs market is segmented on the basis of product, application, source, and region. Based on product, the market is bifurcated into vaccines, blood & blood products, allergenic extracts, human cells & tissues, gene therapies, protein, cellular therapies, and xenotransplantation products. By application, it is categorized into rheumatoid arthritis, anemia, cancer, diabetes, and others. In terms of source, it is classified into humans, avian cell culture, yeast, bacteria, insect cell culture, and xenotransplantation products. Geographically, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

The study provides an in-depth analysis of the biologic therapeutics drugs market with current trends and future estimations to elucidate investment pockets.
Comprehensive analysis of factors that drive and restrict the growth of the market has been provided.
The report offers a quantitative analysis to assist stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of different segments helps determine various products available in the market.
Key players have been profiled and their strategies thoroughly analyzed to predict the competitive market outlook.

Biologic Therapeutics Drugs Market Key Segments:

By Product

Vaccines
Blood and Blood Products
Allergenic Extracts
Human Cells and Tissues
Gene Therapies
Proteins
Cellular Therapies
Xenotransplantation Products

By Application

Rheumatoid Arthritis
Anemia
Cancer
Diabetes
Others

By Source

Humans
Avian Cell Culture
Yeast
Bacteria
Insects Cell Culture
Transgenics

By Geography

North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
LAMEA
- Latin America
- The Middle East
- Africa

List of players profiled in the report

Pfizer Inc.
AstraZeneca
Novartis Global
Merck & Co. Inc.
Smith Medical
GlaxoSmithKline Plc.
Concord Biotech
Aurobindo Pharma Ltd.
H. Lundbeck A/S
Retractable Technologies, Inc.

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

Chapter: 4 BIOLOGIC THERAPEUTICS MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. VACCINES

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. BLOOD AND BLOOD PRODUCTS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. ALLERGENIC EXTRACTS

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. HUMAN CELLS AND TISSUES

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. GENE THERAPIES

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

4.7. PROTEINS

4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast

4.8. CELLULAR THERAPIES

4.8.1. Key market trends
4.8.2. Growth factors and opportunities
4.8.3. Market size and forecast

4.9. XENOTRANSPLANTATION PRODUCTS

4.9.1. Key market trends
4.9.2. Growth factors and opportunities
4.9.3. Market size and forecast

Chapter: 5 BIOLOGIC THERAPEUTICS DRUGS MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. RHEUMATOID ARTHRITIS

5.2.1. Market size and forecast

5.3. ANEMIA

5.3.1. Market size and forecast

5.4. CANCER

5.4.1. Market size and forecast

5.5. DIABETES

5.5.1. Market size and forecast

5.6. OTHERS

5.6.1. Market size and forecast

Chapter: 6 BIOLOGIC THERAPEUTICS DRUGS MARKET, BY SOURCE

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. HUMANS

6.2.1. Market size and forecast

6.3. AVIAN CELL CULTURE

6.3.1. Market size and forecast

6.4. YEAST

6.4.1. Market size and forecast

6.5. BACTERIA

6.5.1. Market size and forecast

6.6. INSECTS CELL CULTURE

6.6.1. Market size and forecast

6.7. TRANSGENICS

6.7.1. Market size and forecast

Chapter: 7 BIOLOGIC THERAPEUTICS DRUGS MARKET, BY REGION

7.1. OVERVIEW
7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast

7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast

7.2.4. North America Biologic Therapeutics Drugs Market by Product
7.2.5. North America Biologic Therapeutics Drugs Market by Application
7.2.6. North America Biologic Therapeutics Drugs Market by Source

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast

7.3.3.1. UK market size and forecast
7.3.3.2. Germany market size and forecast
7.3.3.3. France market size and forecast
7.3.3.4. Spain market size and forecast
7.3.3.5. Italy market size and forecast
7.3.3.6. Rest of Europe market size and forecast

7.3.4. Europe Biologic Therapeutics Drugs Market by Product
7.3.5. Europe Biologic Therapeutics Drugs Market by Application
7.3.6. Europe Biologic Therapeutics Drugs Market by Source

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast

7.4.3.1. China market size and forecast
7.4.3.2. Japan market size and forecast
7.4.3.3. India market size and forecast
7.4.3.4. Rest of Asia-Pacific market size and forecast

7.4.4. Asia-Pacific Biologic Therapeutics Drugs Market by Product
7.4.5. Asia-Pacific Biologic Therapeutics Drugs Market by Application
7.4.6. Asia-Pacific Biologic Therapeutics Drugs Market by Source

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast

7.5.3.1. Latin America market size and forecast
7.5.3.2. The Middle East market size and forecast
7.5.3.3. Africa market size and forecast

7.5.4. LAMEA Biologic Therapeutics Drugs Market by Product
7.5.5. LAMEA Biologic Therapeutics Drugs Market by Application
7.5.6. LAMEA Biologic Therapeutics Drugs Market by Source

Chapter: 8 COMPANY PROFILES

8.1. PFIZER INC.

8.1.1. Operating business segments
8.1.2. Business performance
8.1.3. Key strategic moves and developments

8.2. ASTRAZENECA

8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments

8.3. NOVARTIS GLOBAL

8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments

8.4. MERCK & CO. INC.

8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments

8.5. SMITH MEDICAL

8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments

8.6. GLAXOSMITHKLINE PLC.

8.6.1. Operating business segments
8.6.2. Business performance
8.6.3. Key strategic moves and developments

8.7. CONCORD BIOTECH

8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments

8.8. AUROBINDO PHARMA LTD.

8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments

8.9. H. LUNDBECK A/S

8.9.1. Operating business segments
8.9.2. Business performance
8.9.3. Key strategic moves and developments

8.10. RETRACTABLE TECHNOLOGIES, INC.

8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Shopping Cart is Empty..

Your Shopping Cart Is Empty

Biologic Therapeutics Drugs Market Key Segments:

By Product

By Application

By Source

By Geography

PURCHASE OPTIONS

Reach out to us

Request TOC/Sample

Request Customization

Request TOC/Sample

Why Allied Market Research

Infallible Methodology

Analyst Support

Customization

TARGETED MARKET VIEW

Featured Reports

Featured Readings

Get Fresh content delivered

About

Contact Us

Find Help

Get notification about our new releases

Our Products & Services

CONNECT WITH US

Press Media

We Accept